Abstract 116P
Background
Precision medicine, a tailored approach based on tumor profiling and actionable genetic mutations detection, is the new paradigm for oncologic patients management. An increasing number of genes is tested after new targeting drug approvals with high impacts in terms of costs and report turnaround time.
Methods
Using Diaceutics Data Repository, a global multi source database including commercial claims and laboratory data, we analyzed testing and positivity rate to compare the 2022 and 2023 diagnostic activity of the laboratory.
Results
2023 data analysis reveals NGS as the primary method used currently for the majority of tumors such as lung (90%), colorectal cancers (70%) and melanoma (78%) while in 2022 the sequential testing approach by real time PCR and FISH was the standard approach for all samples. Following the approval of new drugs in 2022, the laboratory also covers in 2023 new disease entities by NGS testing such as cholangiocarcinoma and endometrial cancer. Immunohistochemistry also encountered consistent changes: ALK5A4 antibody is now only used as a confirmatory tool for ALK gene rearrangements (previously detected by molecular testing); PAN-TRK antibody used for NTRK genes fusions screening increased and PD-L1 testing is also performed in colorectal, melanoma, head and neck squamous cancers in addition to lung adenocarcinoma.
Conclusions
Our laboratory successfully experienced a switch to NGS sequencing technology in a very short time. An automated system for library preparation was shown to be helpful for results standardization and sample tracking in a laboratory not so experienced in molecular approaches. We also demonstrated that little customized panels are suitable to detect actionable genetic alterations as recommended by International Guidelines. A parallel sequencing approach introduced in the routine of a middle size public pathology laboratory is possible and cost effective.
Editorial acknowledgement
We would like to thank Diaceutics PLC who provided data and analytic support on their DXRX platform for this research.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
125P - Combination of navitoclax with alpelisib and trametinib to synergistically impair cell viability in high-grade ovarian cancer
Presenter: Lisa Wozelka-Oltjan
Session: Cocktail & Poster Display session
Resources:
Abstract
126P - Effect of sequential antitumoral treatment with immune checkpoint blockade and tyrosine kinase inhibitors in hepatocellular carcinoma
Presenter: Vincenza Ciaramella
Session: Cocktail & Poster Display session
Resources:
Abstract
127P - Novel bone-targeting of activatable sirolimus for targeted therapy of bone-resident cancers
Presenter: Alistare Sadra
Session: Cocktail & Poster Display session
Resources:
Abstract
128P - Network medicine approach identifies small molecule drugs as immune checkpoint inhibitors repurposable for rectal cancer
Presenter: Faheem Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
129P - Repurposing existing therapies for adrenal cancer: Unlocking new possibilities
Presenter: Anupama Samantasinghar
Session: Cocktail & Poster Display session
Resources:
Abstract
130P - Restoration of the mutant p53 protein upon treatment with small molecule modulators
Presenter: Elvina Gilyazova
Session: Cocktail & Poster Display session
Resources:
Abstract
131P - Trop 2 and its overexpression in metastatic colorectal cancer patients (mCRCp): Biological, clinical and therapeutic implications
Presenter: Andrea Mancuso Petricca
Session: Cocktail & Poster Display session
Resources:
Abstract
132P - Novel small molecule modulators for activation of mutant tumor suppressor p53
Presenter: Damir Davletshin
Session: Cocktail & Poster Display session
Resources:
Abstract
133P - Cytotoxic efficacy of artificial vesicles obtained from CAR-T cells by ultrasonication
Presenter: Ekaterina Zmievskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
134P - Doxorubicin and olaparib (OLA) synergism in high-grade serous ovarian (HGOC) and triple-negative breast cancer (TNBC) cell lines with olaparib-resistance
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract